Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores-Reference-Cited by-同舟云学术

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores

Published:2021-06-29 Issue:12 Volume:81 Page:874-881
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Wenzel Mike¹²^ORCID,Würnschimmel Christoph²³^ORCID,Ruvolo Claudia C.²⁴^ORCID,Nocera Luigi²⁵^ORCID,Tian Zhe²,Saad Fred²,Briganti Alberto⁵,Tilki Derya³⁶^ORCID,Graefen Markus³,Kluth Luis A.¹,Mandel Philipp¹,Chun Felix K.H.¹,Karakiewicz Pierre I.²

Affiliation:

1. Department of Urology, University Hospital Frankfurt Goethe University Frankfurt am Main Germany

2. Cancer Prognostics and Health Outcomes Unit, Division of Urology University of Montréal Health Center Montréal Québec Canada

3. Martini‐Klinik Prostate Cancer Center University Hospital Hamburg‐Eppendorf Hamburg Germany

4. Department of Neurosciences, Reproductive Sciences and Odontostomatology University of Naples Federico II Naples Italy

5. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute IBCAS San Raffaele Scientific Institute Milan Italy

6. Department of Urology University Hospital Hamburg‐Eppendorf Hamburg Germany

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24184

Reference28 articles.

1. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

2. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations

3. “Reverse Stage Migration”: What Can Population-based Data Tell Us About Trends in Prostate Cancer Presentation?

4. Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry

5. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate‐specific antigen screening in 2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting;Journal of the American Geriatrics Society;2024-06-26

3. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials;European Urology;2024-05

4. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol;European Urology Oncology;2023-10

5. Putting patients first to redefine prostate cancer classifications;JNCI: Journal of the National Cancer Institute;2023-07-10